Allogene Therapeutics Shares Rise 36% on Trial

Allogene Therapeutics shares jumped 36% after interim ALPHA3 trial showed 58.3% MRD clearance versus 16.7% in control.
The trial’s futility analysis revealed a 41.6% absolute MRD clearance gap, surpassing the 25‑30% clinical benchmark.
Day‑45 assessment showed median 97.7% ctDNA drop in cema‑cel arm versus 26.6% rise in observation arm among 24 patients.
No severe adverse events reported; 10 of 12 treated patients were managed entirely outpatient, and community centers contributed ~33% of enrollments.